[go: up one dir, main page]

AR090972A1 - Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf - Google Patents

Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf

Info

Publication number
AR090972A1
AR090972A1 ARP130101566A AR090972A1 AR 090972 A1 AR090972 A1 AR 090972A1 AR P130101566 A ARP130101566 A AR P130101566A AR 090972 A1 AR090972 A1 AR 090972A1
Authority
AR
Argentina
Prior art keywords
weeks
vegf
patient
vegf therapy
resistant patients
Prior art date
Application number
Other languages
English (en)
Inventor
C Hohman Thomas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR090972A1 publication Critical patent/AR090972A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para el tratamiento de un paciente que tiene una afección ocular, por ejemplo, degeneración macular relacionada con la edad o edema macular diabético, a través de la administración de una proteína de unión recombinante que comprende un dominio de repetición de anquirina. Se puede administrar la composición entre cada 8 semanas y cada 16 semanas. El paciente que se está tratando puede ser resistente a las terapias anti-VEGF actuales. Reivindicación 1: Uso de una proteína de unión recombinante que comprende un dominio de repetición de anquirina, en donde el dominio de anquirina se une a VEGF-Axxx con una Kd inferior a 10⁹ M, caracterizado porque es para la preparación de un medicamento útil para inhibir la unión entre VEGF-Axxx y VEGFR-2 en un paciente que necesite dicha inhibición, administrándose con una frecuencia de entre 8 semanas y 16 semanas una dosis de entre 1 mg y 4 mg.
ARP130101566 2012-05-07 2013-05-07 Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf AR090972A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643878P 2012-05-07 2012-05-07
US201261728017P 2012-11-19 2012-11-19
US201261731238P 2012-11-29 2012-11-29

Publications (1)

Publication Number Publication Date
AR090972A1 true AR090972A1 (es) 2014-12-17

Family

ID=48446670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101566 AR090972A1 (es) 2012-05-07 2013-05-07 Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf

Country Status (10)

Country Link
US (3) US10568934B2 (es)
EP (2) EP3646880A1 (es)
AR (1) AR090972A1 (es)
DK (1) DK2846836T3 (es)
ES (1) ES2753135T3 (es)
HU (1) HUE046134T2 (es)
PL (1) PL2846836T3 (es)
PT (1) PT2846836T (es)
TW (1) TW201350128A (es)
WO (1) WO2013169614A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
SI2956476T1 (sl) * 2013-02-18 2020-03-31 Vegenics Pty Limited Molekule za vezavo na ligande in uporabe le-teh
DK3065761T3 (da) * 2013-11-05 2020-02-17 Allergan Inc Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3973977A1 (en) 2015-03-31 2022-03-30 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
LT3795181T (lt) * 2016-06-16 2025-12-29 Adverum Biotechnologies, Inc. Amd gydymas naudojant aav2 variantą su afliberceptu
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
US11519020B2 (en) * 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0781331B1 (en) 1994-08-20 2008-09-03 Gendaq Limited Improvements in or relating to binding proteins for recognition of dna
US5932440A (en) 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
US5827692A (en) 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
CA2296508A1 (en) 1997-07-18 1999-01-28 Yale University Structure of the ankyrin binding domain of a alpha-na,k-atpase
AU775076B2 (en) 1998-12-10 2004-07-15 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US20020042094A1 (en) 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
EP1266004A2 (en) 2000-02-17 2002-12-18 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
AU2001278859A1 (en) 2000-06-29 2002-01-14 University Of Florida Ubiquitin ligase
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
US20060121045A1 (en) 2004-11-08 2006-06-08 Brent Iverson Antibody fragments for protection from pathogen infection and methods of use thereof
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
NZ580670A (en) 2007-06-21 2011-09-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
WO2009115919A2 (en) 2008-03-19 2009-09-24 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818969C (en) 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
DK3065761T3 (da) 2013-11-05 2020-02-17 Allergan Inc Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin

Also Published As

Publication number Publication date
US10568934B2 (en) 2020-02-25
EP2846836B1 (en) 2019-08-14
US20130296238A1 (en) 2013-11-07
US20200405808A1 (en) 2020-12-31
WO2013169614A1 (en) 2013-11-14
DK2846836T3 (da) 2019-11-11
US20220096596A1 (en) 2022-03-31
EP2846836A1 (en) 2015-03-18
ES2753135T3 (es) 2020-04-07
TW201350128A (zh) 2013-12-16
EP3646880A1 (en) 2020-05-06
HUE046134T2 (hu) 2020-02-28
PT2846836T (pt) 2019-10-29
PL2846836T3 (pl) 2020-01-31

Similar Documents

Publication Publication Date Title
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX385629B (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
MX2017005875A (es) Metodos para tratar enfermedades oculares.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
EA201490495A1 (ru) Новые легкоразрушающиеся ингибиторы rock
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
AR111491A1 (es) Métodos para tratar enfermedades pediátricas
BR112015012497A2 (pt) combinações farmacêuticas
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
FB Suspension of granting procedure